69 related articles for article (PubMed ID: 38583073)
1. Long-term safety of fezolinetant in Chinese women with vasomotor symptoms associated with menopause: the phase 3 open-label MOONLIGHT 3 clinical trial.
Yu Q; Ming F; Ma J; Cai Y; Wang L; Ren M; Zhang J; Ma X; Miyazaki K; He W; Wang X
J Int Med Res; 2024 May; 52(5):3000605241246624. PubMed ID: 38818887
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of fezolinetant for moderate to severe vasomotor symptoms associated with menopause among women in East Asia: a phase 3 randomized study (MOONLIGHT I).
Ruan X; Bai W; Ren M; Kim T; Lee JY; Chuang FC; Wang PH; He W; Ma X; Miyazaki K; Song N; Wang X; Yu Q
J Int Med Res; 2024 May; 52(5):3000605241247684. PubMed ID: 38818888
[TBL] [Abstract][Full Text] [Related]
3. Phase II study of fezolinetant for treatment of vasomotor symptoms associated with menopause in Japan.
Takamatsu K; Miki T; Miyazaki K; Hashimoto A; He W; Wang X
Climacteric; 2024 Jun; ():1-9. PubMed ID: 38864290
[TBL] [Abstract][Full Text] [Related]
4. Treating moderate-to-severe menopausal vasomotor symptoms with fezolinetant: analysis of responders using pooled data from two phase 3 studies (SKYLIGHT 1 and 2).
Nappi RE; Johnson KA; Stute P; Blogg M; English M; Morga A; Scrine L; Siddiqui E; Ottery FD
Menopause; 2024 Jun; 31(6):512-521. PubMed ID: 38626380
[TBL] [Abstract][Full Text] [Related]
5. Effect of fezolinetant on sleep disturbance and impairment during treatment of vasomotor symptoms due to menopause.
Shapiro C M M; Cano A; Nappi RE; Santoro N; English ML; Mancuso S; Morga A; Siddiqui E; Valluri U; Ottery FD
Maturitas; 2024 Aug; 186():107999. PubMed ID: 38749864
[TBL] [Abstract][Full Text] [Related]
6. Validation and Application of Thresholds to Define Meaningful Change in Vasomotor Symptoms Frequency: Analysis of Pooled SKYLIGHT 1 and 2 Data.
Morga A; Zimmermann L; Valluri U; Siddiqui E; McLeod L; Bender RH
Adv Ther; 2024 Jul; 41(7):2845-2858. PubMed ID: 38775925
[TBL] [Abstract][Full Text] [Related]
7. Efficacy evaluation of standardized
Dubey VP; Sureja VP; Kheni DB
J Biomed Res; 2024 Apr; 38(3):278-286. PubMed ID: 38646867
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of fezolinetant for vasomotor symptoms in postmenopausal women: A systematic review and meta-analysis of randomized controlled trials.
Khan MS; Muneeb Akhtar SM; Asghar MS
Int J Gynaecol Obstet; 2024 Jun; ():. PubMed ID: 38881196
[No Abstract] [Full Text] [Related]
9. Letter to the Editor: Efficacy and safety of fezolinetant for vasomotor symptoms in postmenopausal women: A systematic review and meta-analysis of randomized controlled trials.
Douxfils J; Beaudart C; Dogné JM
Int J Gynaecol Obstet; 2024 Jun; ():. PubMed ID: 38881190
[No Abstract] [Full Text] [Related]
10. Could menopause drug fezolinetant show promise for vasomotor symptoms associated with androgen deprivation therapy?
Qin KR; Mertens E; Tempo JA; Perera M; Brennan J
Transl Androl Urol; 2024 May; 13(5):920-922. PubMed ID: 38855582
[No Abstract] [Full Text] [Related]
11. Totality of evidence refutes neoplasm risk with fezolinetant.
Neal-Perry G; Santoro N; Cano A; Nappi RE; Shapiro M; Ottery FD
Lancet; 2024 May; 403(10440):1987-1988. PubMed ID: 38762322
[No Abstract] [Full Text] [Related]
12. Totality of evidence refutes neoplasm risk with fezolinetant - Authors' reply.
Douxfils J; Beaudart C; Dogné JM
Lancet; 2024 May; 403(10440):1988. PubMed ID: 38762323
[No Abstract] [Full Text] [Related]
13. Treatment of Menopausal Vasomotor Symptoms With Fezolinetant, a Neurokinin 3 Receptor Antagonist: A Phase 2a Trial.
Depypere H; Timmerman D; Donders G; Sieprath P; Ramael S; Combalbert J; Hoveyda HR; Fraser GL
J Clin Endocrinol Metab; 2019 Dec; 104(12):5893-5905. PubMed ID: 31415087
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness and safety of fezolinetant in alleviating vasomotor symptoms linked to Menopause.: A systematic review and Meta-Analysis.
Elnaga AAA; Alsaied MA; Elettreby AM; Ramadan A
Eur J Obstet Gynecol Reprod Biol; 2024 Jun; 297():142-152. PubMed ID: 38640780
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and Safety of Fezolinetant for the Treatment of Menopause-Associated Vasomotor Symptoms: A Meta-analysis.
Bonga KN; Mishra A; Maiti R; Padhy BM; Meher BR; Srinivasan A
Obstet Gynecol; 2024 Mar; 143(3):393-402. PubMed ID: 38227939
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of fezolinetant for vasomotor symptoms in postmenopausal women: A systematic review and meta-analysis of randomized controlled trials.
Akhtar SMM; Ali A; Khan MS; Khan V; Fareed A; Saleem SZ; Mumtaz M; Ahsan MN; Iqbal S; Asghar MS
Int J Gynaecol Obstet; 2024 Apr; ():. PubMed ID: 38563867
[TBL] [Abstract][Full Text] [Related]
17. Fezolinetant for the treatment of vasomotor symptoms associated with menopause: a meta-analysis.
Chavez MP; Pasqualotto E; Ferreira ROM; Hohl A; de Moraes FCA; Schmidt PHS; Rodrigues ALSO; de Sa JR
Climacteric; 2024 Jun; 27(3):245-254. PubMed ID: 38619017
[TBL] [Abstract][Full Text] [Related]
18. Menopausal symptom management: Fezolinetant's varied doses provide effective relief for vasomotor symptoms in women - A meta-analysis of 3291 participants.
Elhusein AM; Fadlalmola HA; Abedelwahed HH; Elshaikh AA; Banaga AE; Alrahman MHF; Abdelgadim NH; Mohammed IH; Abdalla AAA; Abdalla FAM; Abd Allah EM; Abbas NI; Alhujaili AD; Almkiy EA; Idress EA; Awadalkareem EM; Abdeldafie SY; Balusamy P; Mohamed RA; Aloufi RSM; Habiballa M; Abdelmalik MA; Alhejaili MM; Ibrahim IA; Masaad HK
Afr J Reprod Health; 2024 Mar; 28(3):99-113. PubMed ID: 38583073
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]